{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:52:38Z","timestamp":1770965558609,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T00:00:00Z","timestamp":1266969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Although one defining characteristic of second generation H<jats:sub>1<\/jats:sub>\u2010antihistamines is their lack of CNS effects, it has been proved that some compounds of this group are not devoid of such effects.<\/jats:p><jats:p>\u2022\u2003There is evidence that second generation H<jats:sub>1<\/jats:sub>\u2010antihistamine compounds without relevant CNS effects at therapeutic doses could increase the behavioural impairment produced by sedating drugs when both are taken concomitantly.<\/jats:p><jats:p>\u2022\u2003The evaluation of possible drug interactions is crucial, especially when both compounds could have CNS effects, due to the possible consequences at the patient safety level.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003The study demonstrates the lack of CNS effects after repeated administration at therapeutic doses of the unique second generation H<jats:sub>1<\/jats:sub>\u2010antihistamine with anti\u2010PAF activity.<\/jats:p><jats:p>\u2022\u2003The study demonstrates the lack of interaction between repeated administration of rupatadine 10\u2003mg and a single oral dose of lorazepam 2\u2003mg.<\/jats:p><jats:p>\u2022\u2003The study presents a useful design to evaluate the interaction between two compounds saving time and the exposure of the volunteers to medication.<\/jats:p><jats:p><jats:bold>AIM<\/jats:bold>The main objective was to assess whether benzodiazepine intake when rupatadine plasma concentrations were at steady\u2010state would increase the CNS depressant effects. Rupatadine is a new H<jats:sub>1<\/jats:sub>\u2010antihistamine which also inhibits platelet activating factor (PAF) release and has been shown to be clinically effective at doses of 10\u2003mg.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold>Sixteen healthy young volunteers took part in a crossover, randomized, double\u2010blind, placebo controlled trial comprising two experimental periods (repeated administration for 7 days of rupatadine 10\u2003mg or placebo as single oral daily doses, separated by a washout of 14 days). On days 5 and 7, according to a fully balanced design, a single oral dose of lorazepam 2\u2003mg or placebo was added. CNS effects were evaluated on these days by seven objective tests of psychomotor performance and eight subjective visual analogue scales (VAS) at pre\u2010dose and several times after drug intake. Four treatment conditions were evaluated: placebo, rupatadine 10\u2003mg, lorazepam 2\u2003mg and rupatadine 10\u2003mg + lorazepam 2\u2003mg.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>Significant CNS effects, either impairment of psychomotor performance or subjective sedation, were observed when lorazepam was administered, either alone or in combination with steady state concentrations of rupatadine. No significant differences were found between these two conditions. In addition, rupatadine was not different from placebo. All treatments were well tolerated.<\/jats:p><jats:p><jats:bold>CONCLUSION<\/jats:bold>Repeated doses of rupatadine (10\u2003mg orally) did not enhance the CNS depressant effects of lorazepam (2\u2003mg orally, single dose) either in objective psychomotor tasks or in subjective evaluations.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03648.x","type":"journal-article","created":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T08:57:00Z","timestamp":1267001820000},"page":"663-674","source":"Crossref","is-referenced-by-count":13,"title":["Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double\u2010blind, crossover, repeated dose, placebo\u2010controlled study"],"prefix":"10.1111","volume":"69","author":[{"given":"Consuelo","family":"Garc\u00eda\u2010Gea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosa","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Maria","family":"Antonijoan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Donado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1aki","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel\u2010Jos\u00e9","family":"Barbanoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.43.3.245"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.44.5.430"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0001-4575(85)90032-6"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-9725.2002.00031.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118891"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1550"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1077(200010)15:1 <::AID-HUP247>3.0.CO;2-S"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.962"},{"key":"e_1_2_7_10_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-3565(24)36413-4","article-title":"Rupatadine, a new potent, orally active dual antagonist of histamine and platelet\u2010activating factor (PAF)","volume":"280","author":"Merlos M","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.14.1989"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000080959"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.741"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470060102"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470060203"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470060303"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-8986.3940409"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.09.002"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04406.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00428325"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174511"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00429732"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb02792.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00210844"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(84)90248-X"},{"key":"e_1_2_7_26_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0022-3565(25)38262-5","article-title":"Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: antagonism and precipitated withdrawal","volume":"265","author":"Griffiths RR","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62855-4"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00544062"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1989.tb02754.x"},{"key":"e_1_2_7_30_2","first-page":"98","article-title":"The effect of single dose of 120\u2003mg and 240\u2003mg of terfenadine on driving and other measures of psychomotor performance including visual evoked responses","volume":"66","author":"Betts TA","year":"1991","journal-title":"Ann Allergy"},{"key":"e_1_2_7_31_2","first-page":"97","article-title":"Cetirizine 10 and 20\u2003mg impair psychomotor performance","volume":"20","author":"Riedel WJ","year":"1990","journal-title":"Clin Exp Allergy"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00543979"},{"key":"e_1_2_7_33_2","first-page":"285","article-title":"A comparison of central and peripheral effects of cetirizine and loratadine","volume":"19","author":"Percharder JC","year":"1991","journal-title":"J Int Med Res"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31818b2091"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558262"},{"key":"e_1_2_7_36_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF00280119","article-title":"Effects of loratadine and cetirizine on actual driving and psychometric test performance and EEG during driving","volume":"42","author":"Ramaekers JG","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470070402"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00716383"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00981126"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb05694.x"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427672"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427673"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00637593"},{"key":"e_1_2_7_44_2","first-page":"909","article-title":"Pharmacodynamic studies of a combination of lorazepam and diphenhydramine and its single components: electroencephalographic brain mapping and safety evaluation","volume":"44","author":"Saletu B","year":"1988","journal-title":"Curr Ther Res"},{"key":"e_1_2_7_45_2","first-page":"938","article-title":"Pharmacodynamic studies of a combination of lorazepam and diphenhydramine and its single components: psychometric and psychophysiological data","volume":"44","author":"Gr\u00fcnberger J","year":"1988","journal-title":"Curr Ther Res"},{"issue":"49","key":"e_1_2_7_46_2","first-page":"62","article-title":"Adverse behavioural events reported in patients taking alprazolam and other benzodiazepines","volume":"54","author":"Cole JO","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/026988110201600104"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb01745.x"},{"key":"e_1_2_7_49_2","first-page":"135","article-title":"Psychometric of drug effects in volunteers and patients","volume":"3","author":"Hindmarch I","year":"1988","journal-title":"Pharm Med"},{"key":"e_1_2_7_50_2","first-page":"51","article-title":"Proof of safety of drugs: focus on vigilance","volume":"24","author":"Barbanoj MJ","year":"2002","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00549598"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.856"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03648.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03648.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T21:26:05Z","timestamp":1739913965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03648.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,10]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03648.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03648.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,10]]}}}